BETHLEHEM, Pa., Aug. 9, 2011 /PRNewswire/ -- In its efforts to further advance best practices with the continuous improvement of safety, B. Braun Medical Inc. (B. Braun) announced today that its OnGuard™ Contained Medication System can help increase institution and new legislation compliance regarding the protection of healthcare workers from exposure to hazardous drugs.
Senate Bill 5594 has recently directed The Washington State Department of Labor & Industries to adopt requirements for the handling of hazardous drugs in protecting healthcare workers from occupational drug exposure. Rules focused on proper ventilation, protective equipment, and safe handling practices have been addressed in detail. Amid many reports nationally on the adverse health effects of occupational hazardous drug exposure, Washington is the first state in the nation to require such protection for its workers.
Studies have shown certain drugs, such as chemotherapy agents, can be associated with a variety of both short-term and long-term health effects.(1) OnGuard is a next-generation closed system drug-transfer device. The innovative drug admixture and delivery system meets The American Society of Health-System Pharmacists (ASHP), National Institute for Occupational Safety and Health (NIOSH) and USP <797> safety guidelines and provides a new level of hazard protection for pharmacists and nurses on the frontline of chemotherapy preparation and administration.
"When you're preparing chemo every day and there is the looming threat of exposure to hazardous vapors, protecting your personal safety is of the utmost importance," said Chris Mangen of the Lucy Curci Cancer Center in Rancho Mirage, Calif. "The OnGuard system is easy-to-use and safe, helping eliminate the risks associated with typical chemo preparation."
Prior to Bill 5594, ASHP, NIOSH and USP <797> had each recommended the use of protective devices for the preparation of hazardous medications. After its passing, NIOSH teamed up with OSHA and The Joint Commission, sending a letter to all U.S. hospitals reinforcing the need to address safe drug handling at their facilities.
"This message has been out there, and with the passing of Bill 5594 it's becoming even stronger," said Rob Albert, Vice President, Pharmaceutical Marketing, B. Braun Medical Inc. "An investment in OnGuard is an opportunity for facilities to invest in and protect their most valuable assets – the health and well being of employees and patients."
About B. Braun
B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.
Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, email us at email@example.com or visit B. Braun at www.bbraunusa.com.
(1) CDC. NIOSH Alert: Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Page 1. September 2004.
SOURCE B. Braun Medical Inc.